UCB SA chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share 30.90
Dividend & YieldN/A£ (N/A)
Beta 0.38
Market capitalization N/A
Operating cash flow 1.46B
ESG Scores 16.8

Company description

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; BIMZELX for treating psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa; and dapirolizumab pegol for systemic lupus erythematosus. In addition, the company is involved in developing rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan to treat myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam to treat tereotypical prolonged seizure; Bepranemab to treat Alzheimer's disease; and UCB0599 to treat Parkinson's disease. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. It operates in the United States, Japan, Germany, rest of Europe, Spain, France, Italy, the United Kingdom, Ireland, China, Belgium, and internationally. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.

Sector: - Industry:

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities 69M 60M 258M 431M
Total Cashflows From Investing Activities -320M -235M -2.23B -487M
Net Borrowings -202M -241M 1.44B -756M
Total Cash From Financing Activities -538M -605M 1.18B -1.12B
Change To Operating Activities 6M -16M -123M
Issuance Of Stock 150M 150M 150M
Net Income 800M 792M 732M 1.06B
Change In Cash 215M 51M 15M -60M
Effect Of Exchange Rate -16M 9M -15M -7M
Total Cash From Operating Activities 1.09B 882M 1.08B 1.55B
Depreciation 288M 313M 354M 323M
Change To Account Receivables -32M -147M -105M -247M
Other Cashflows From Financing Activities -63M -59M -70M -63M
Change To Netincome 36M 9M 37M 19M
Capital Expenditures -94M -99M -256M -282M

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development 1.16B 1.27B 1.57B 1.63B
Income Before Tax 1.01B 961M 880M 1.23B
Net Income 800M 792M 732M 1.06B
Selling General Administrative 1.14B 1.3B 1.42B 1.55B
Gross Profit 3.43B 3.65B 3.98B 4.34B
Ebit 1.11B 1.11B 1.04B 1.31B
Operating Income 1.11B 1.11B 1.04B 1.31B
Interest Expense -62M -60M -68M -45M
Income Tax Expense 200M 146M 119M 170M
Total Revenue 4.63B 4.91B 5.35B 5.78B
Cost Of Revenue 1.2B 1.27B 1.36B 1.44B
Total Other Income ExpenseNet -97M -150M -156M -89M
Net Income From Continuing Ops 815M 815M 761M 1.05B
Net Income Applicable To Common Shares 800M 792M 732M 1.06B

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 4.26B 4.07B 6.05B 5.82B
Total Stockholder Equity 6.31B 7.04B 7.27B 8.39B
Other Current Liabilities 317M 336M 436M 536M
Total Assets 10.51B 11.08B 13.32B 14.21B
Common Stock 584M 584M 584M 584M
Other Current Assets 108M 188M 283M 230M
Retained Earnings 4.39B 4.96B 5.46B 6.29B
Treasury Stock -698M -539M -806M -522M
Cash 1.26B 1.29B 1.34B 1.26B
Total Current Liabilities 2.15B 2.39B 2.81B 2.82B
Other Stockholder Equity -356M -162M -413M -127M
Property, Plant, and Equipment 805M 840M 1.03B 1.27B
Total Current Assets 2.95B 3.29B 3.58B 3.71B
Net Tangible Assets 447M 1.12B -666M 54M
Net Receivables 821M 880M 939M 1.13B
Accounts Payable 481M 503M 599M 677M


Insider Transactions

Here are the insider transactions of stock shares related to UCB SA:

Filer Name Transaction Text Ownership Date Filer Relation Shares
NO DATA

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to UCB SA. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on UCB SA

Here is the result of two systematic investment strategies applied to UCB SA. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on UCB SA

The following chart shows the equity curve of the two systematic investment strategies applied to UCB SA:

UCB SA automated entries

The systematic investment strategy that buys the first day of the month would give a performance of 18.45% on the backtest period.

Performance at glance

Performance

18.45 %

Latent gain

98.56 £

Invested capital

534.27 £

Annualized return

24.93 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on UCB SA

This is the result of two momentum investment strategies applied to UCB SA. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on UCB SA

The following chart shows all the entries opened by the momentum investment system on UCB SA:

UCB SA momentum entries
  • The first momentum investment strategy would give 15.6% of return on UCB SA. That represents 170.84£ of latent gain with 1094.82£ of employed capital.
  • The second momentum investment strategy would give 12.15% of return on UCB SA. That represents 34.27£ of latent gain with 282.14£ of employed capital.
Performance at glance (1Q Momentum)

Performance

15.6 %

Latent gain

170.84 £

Invested capital

1094.82 £

Annualized return

-0.0 %
Performance at glance (2Q Momentum)

Performance

12.15 %

Latent gain

34.27 £

Invested capital

282.14 £

Annualized return

46.73 %

Momentum equity curve on UCB SA

The following chart shows the equity curve of the two momentum strategies applied to UCB SA:

UCB SA momentum equity

Note: the dividends potentially given by UCB SA are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on UCB SA

The following chart shows the employed capital evolution of the two momentum strategies on UCB SA since the beginning:

UCB SA

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250£, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000£.


Buy the dip strategy result on UCB SA

Buy the dip entry openings on UCB SA

UCB SA

The performance achieved by the robo-advisor on UCB SA is 0%. That represents 0.0$ of latent gain with 0.0£ of employed capital. The following chart shows UCB SA stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of UCB SA, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

0 %

Latent gain

0.0 £

Invested capital

0.0 £

Annualized return

-0.0 %

Equity curve of the strategy applied to UCB SA

The following chart shows the result of the investment strategy applied to UCB SA:

UCB SA

Note: the dividends potentially given by UCB SA are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on UCB SA

The following chart shows the employed capital evolution since the beginning of the investment strategy on UCB SA:

UCB SA

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on UCB SA

In this section, I will compare the three previous investment strategies applied to UCB SA.

Equity curve comparison on UCB SA

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

UCB SA investment strategy comparison

Employed capital comparison on UCB SA

UCB SA investment comparison

Performance comparison on UCB SA

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment 18.45% 98.56£ 534.27£ 24.93%
Momentum 1 quarter 15.6% 170.84£ 1094.82£ 31.2%
Momentum 2 quarters 12.15% 34.27£ 282.14£ 46.73%
Non-directional 0% 0.0£ 0.0£ -0.0%
Annualized return comparison

Automatic investment

24.93 %

Momentum 1Q

46.73 %

Momentum 2Q

46.73 %

Non-directional

-0.0 %

Correlated stocks

Here are the most positively and negatively correlated stocks with UCB SA:

Positive correlations

Most correlated stocks this year


Most correlated stocks last 3 months

Negative correlation

Most negatively correlated stocks this year


Most negatively correlated stocks last 3 months

Note: The algorithm computes the probability of correlation between UCB SA and the other stocks. There may be false positives or some missing correlated stocks. If the price of UCB SA does not vary for 36 weeks, the correlation calculation result will be wrong.


Company information

Company name UCB SA
Country Belgium
City Brussels
Address Allée de la Recherche, 60
Phone 32 2 559 99 99
Website www.ucb.com
FullTime employees 8600
Industry
Sector
Exchange XLON
Ticker 0NZT.XLON
Market www.londonstockexchange.com

UCB SA ESG Scores

Environment scores

Environment ESG Factors Scores
Environment Score 0.0
Peer Environment Performance 2.0330864197531
Environment Percentile unknown
Palm Oil no
Nuclear no
Fur Leather no
GMO no
Coal no
Pesticides no
Animal Testing yes

Social scores

Social ESG Factors Scores
Social Score 10.0
Peer Social Performance 14.299012345679
Social Percentile unknown
Highest Controversy 1
Peer Highest Controversy Performance 1.8780487804878
Adult no
Gambling no
Alcoholic no
Tobacco no
Catholic no
Controversial Weapons no
Small Arms no
Military Contract no
Peer Count yes

Related Controversy: Society & Community IncidentsBusiness Ethics Incidents


Governance scores

Governance ESG Factors Scores
Governance Score 6.8
Peer Governance Performance 8.8141975308642
Governance Percentile unknown

ESG at glance
Total ESG Scores: 16.8
Environment Score: 0.0
Social Score: 10.0
Governance Score: 6.8

ESG Performance: UNDER_PERF

Peer Group: Pharmaceuticals

Peer Esg Score Performance: 25.306097560976

Rating Year: 2022

Rating Month: 8

Max Age: 86400

Percentile: 15